ongoing

OCEANIC-STROKE is a multicenter, international, randomized, placebo controlled, double-blind, parallel group, event driven phase 3 study. The study treatment, asundexian, is a new type of anticoagulant that inhibits Factor XI and is currently under development to provide further treatment options and improve the standard of care with regard to the risk of bleeding.

The main purpose of this study is to learn whether adding asundexian to standard therapy reduces the risk of another stroke in participants who recently had a non-cardioembolic ischemic stroke or temporary stroke-like symptoms when given in addition to standard antiplatelet therapy.

Study Type

Interventional - Drug

Study Design

Randomized, placebo controlled, double-blind, parallel group, event driven Phase 3 trial

NO. of Countries

36

NO. of Sites

717

NO. of Participants

9300

Study Period

2023 - 2025

Sponsor

Bayer

Back To Top